@article {Singh2007b,
	title = {Simultaneous integrated boost of biopsy proven and MRI defined dominant intra-prostatic lesions to 95 Gray with IMRT: early results of a phase I NCI study},
	journal = {Radiation Oncology},
	volume = {2},
	year = {2007},
	pages = {36},
	publisher = {Department of Radiation Medicine, Roswell Park Cancer Institute, Buffalo, USA singhanu@yahoo com},
	abstract = {<p>BACKGROUND: To assess the feasibility, early toxicity of selective, IMRT-based dose escalation (simultaneous integrated boost) to biopsy proven dominant intra-prostatic lesions visible on MRI METHODS: Patients with localized prostate cancer, an abnormality within the prostate on endorectal coil MRI were eligible All patients underwent a MRI-guided transrectal biopsy at the location of the MRI abnormality Gold fiducial markers were also placed Several days later patients underwent another MRI scan for fusion with the treatment planning CT scan This fused MRI scan was used to delineate the region of the biopsy proven intra-prostatic lesion A 3 mm expansion was performed on the intra-prostatic lesions, defined as a separate volume within the prostate The lesion + 3 mm, the remainder of the prostate + 7 mm received 94 5/75 6 Gray (Gy) respectively in 42 fractions Daily seed position was verified to be within 3 mm RESULTS: Three patients were treated Follow-up was 18, 6, and 3 months respectively Two patients had a single intra-prostatic lesion One patient had 2 intra-prostatic lesions All four intra-prostatic lesions, with margin, were successfully targeted, treated to 94 5 Gy Two patients experienced acute RTOG grade 2 genitourinary (GU) toxicity One had grade 1 gastrointestinal (GI) toxicity All symptoms completely resolved by 3 months One patient had no acute toxicity CONCLUSION: These early results demonstrate the feasibility of using IMRT for simultaneous integrated boost to biopsy proven dominant intra-prostatic lesions visible on MRI The treatment was well tolerated</p>
},
	keywords = {adverse effects/methods, Biopsy, epidemiology, epidemiology/radiotherapy, Follow-Up Studies, Humans, Intensity-Modulated, Magnetic Resonance Imaging, Male, National Cancer Institute (U S ), Patient Selection, Prostatic Neoplasms, Questionnaires, Radiotherapy, Radiotherapy Dosage, United States},
	doi = {10 1186/1748-717X-2-36},
	url = {http://dx doi org/10 1186/1748-717X-2-36},
	author = {Anurag K. Singh and Peter Guion and Nancy Sears-Crouse and Karen Ullman and Sharon Smith and Paul Albert and Gabor Fichtinger and Peter Choyke and Sheng Xu and Jochen Kruecker and Bradford Wood and Axel Krieger and Holly Ning}
}
@article {Susil2003,
	title = {System for MR image-guided prostate interventions: canine study},
	journal = {Radiology},
	volume = {228},
	number = {3},
	year = {2003},
	month = {Sep},
	pages = {886{\textendash}894},
	abstract = {<p>The purpose of this study was to demonstrate the use of a transrectal system that enables precise magnetic resonance (MR) image guidance, monitoring of prostate interventions The system used a closed-bore 1 5-T MR imaging unit, enables one to take advantage of the higher signal-to-noise ratio achieved with traditional magnet designs, which is crucial for accurate targeting, monitoring of prostate interventions In the first of the four canine studies, reliable needle placement, with all needles placed within 2 mm of the desired target site, was achieved In two other studies, MR imaging was used to monitor distribution of injected contrast agent solution (gadopentetate dimeglumine mixed with trypan blue dye) in, around the prostate, thereby confirming that solution had been delivered to the desired tissue, also detecting faulty injections In the final study, accurate placement, MR imaging of brachytherapy seeds in the prostate were demonstrated The described system provides a flexible platform for a variety of minimally invasive MR image-guided therapeutic, diagnostic prostate interventions</p>
},
	keywords = {administration /\&/ dosage, administration /\&/ dosage/diagnostic use, Animals, Brachytherapy, Contrast Media, Dogs, Gadolinium DTPA, Injections, Intralesional, Magnetic Resonance Imaging, Male, methods, Prostate, Prostatic Neoplasms, Radiography, Radiotherapy, Trypan Blue},
	doi = {10 1148/radiol 2283020911},
	url = {http://dx doi org/10 1148/radiol 2283020911},
	author = {Robert Susil and Axel Krieger and Andrew Derbyshire and Attila Tanacs and Whitcomb, Louis L. and Gabor Fichtinger and Ergin Atalar}
}
